Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 13/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2124806 | 0.90 | S1PR1 (0.44) | S1PR1S1PR3KCNH2RET | |
| SCHEMBL2121734 | 0.89 | S1PR1 (0.45) | S1PR1S1PR3KCNH2NR1H2NR1H3 | |
| SCHEMBL2123709 | 0.89 | S1PR1 (0.51) | S1PR1S1PR3KCNH2 | |
| SCHEMBL2130322 | 0.88 | S1PR1 (0.50) | S1PR1S1PR3KCNH2NR1H2NR1H3 | |
| SCHEMBL2124243 | 0.87 | S1PR1 (0.47) | S1PR1S1PR3KCNH2 | |
| SCHEMBL2131561 | 0.87 | S1PR1 (0.52) | S1PR1S1PR3KCNH2NR1H2NR1H3 | |
| Hydrochloric Acid SCHEMBL2123966 | 0.87 | S1PR1 (0.47) | S1PR1S1PR3KCNH2 | |
| SCHEMBL2121020 | 0.86 | S1PR1 (0.53) | S1PR1S1PR3KCNH2NR1H2NR1H3 | |
| SCHEMBL2123033 | 0.86 | S1PR1 (0.47) | S1PR1S1PR3KCNH2 | |
| SCHEMBL2130100 | 0.85 | S1PR1 (0.45) | S1PR1S1PR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101083-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101083-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-2443110-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | Glaxo Group Limited (GB) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010146105-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101083-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885KCNH2 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.